The primary outcome of interest was glycaemic control based on the absolute change in HbA1c from baseline to end of study. Secondary outcomes included changes in cardiovascular risk factors (blood pressure, serum lipid profiles, fasting blood glucose and body weight). The study characteristics were also considered as potential effect modifiers in the current study, including sample size, study location, delivery mechanisms, study duration as well as baseline HbA1c.
Copyright and License information: The Author(s) ©2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this
article to respond.